INTRODUCTION: Neoadjuvant systemic therapy represents an evolving cornerstone in the multidisciplinary management of urological malignancies. While cisplatin-based neoadjuvant chem
Phase 3 RCT with sustained reductions in disease biomarkers and clinical attack frequency from a single administration; rigorous design supports potential practice impact, though long-term durability data remain incomplete.